186 related articles for article (PubMed ID: 27942010)
1. Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.
Belle L; Fransolet G; Somja J; Binsfeld M; Delvenne P; Drion P; Hannon M; Beguin Y; Ehx G; Baron F
PLoS One; 2016; 11(12):e0167997. PubMed ID: 27942010
[TBL] [Abstract][Full Text] [Related]
2. Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease.
Matsushita T; Date M; Kano M; Mizumaki K; Tennichi M; Kobayashi T; Hamaguchi Y; Hasegawa M; Fujimoto M; Takehara K
Am J Pathol; 2017 Apr; 187(4):841-850. PubMed ID: 28189565
[TBL] [Abstract][Full Text] [Related]
3. Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
Molés-Poveda P; Montesinos P; Sanz-Caballer J; de Unamuno B; Piñana JL; Sahuquillo A; Botella-Estrada R
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):241-247. PubMed ID: 29254596
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.
Zerr P; Distler A; Palumbo-Zerr K; Tomcik M; Vollath S; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
Am J Pathol; 2012 Nov; 181(5):1672-80. PubMed ID: 22940072
[TBL] [Abstract][Full Text] [Related]
5. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Tedder TF; Fujimoto M
Blood; 2013 Apr; 121(16):3274-83. PubMed ID: 23422748
[TBL] [Abstract][Full Text] [Related]
6. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
7. Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.
Fransolet G; Ehx G; Somja J; Delens L; Hannon M; Muller J; Dubois S; Drion P; Caers J; Humblet-Baron S; Delvenne P; Beguin Y; Conteduca G; Baron F
J Hematol Oncol; 2016 Jul; 9(1):53. PubMed ID: 27377819
[TBL] [Abstract][Full Text] [Related]
8. CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model.
Lim JY; Ryu DB; Kim TW; Lee SE; Park G; Yoon HK; Min CK
Stem Cell Res Ther; 2020 Jun; 11(1):254. PubMed ID: 32586381
[TBL] [Abstract][Full Text] [Related]
9. Alleviation of chronic GVHD in mice by oral immuneregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect.
Ilan Y; Margalit M; Ohana M; Gotsman I; Rabbani E; Engelhardt D; Nagler A
Hum Immunol; 2005 Mar; 66(3):231-40. PubMed ID: 15784461
[TBL] [Abstract][Full Text] [Related]
10. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.
Zhang Y; McCormick LL; Gilliam AC
J Invest Dermatol; 2003 Oct; 121(4):713-9. PubMed ID: 14632186
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma.
Zhou L; Askew D; Wu C; Gilliam AC
J Invest Dermatol; 2007 Feb; 127(2):281-92. PubMed ID: 16917493
[TBL] [Abstract][Full Text] [Related]
12. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
J Invest Dermatol; 2012 Dec; 132(12):2752-61. PubMed ID: 22810302
[TBL] [Abstract][Full Text] [Related]
13. Improvement of Sclerodermatous Graft-Versus-Host Disease in Mice by Niclosamide.
Morin F; Kavian N; Nicco C; Cerles O; Chéreau C; Batteux F
J Invest Dermatol; 2016 Nov; 136(11):2158-2167. PubMed ID: 27424318
[TBL] [Abstract][Full Text] [Related]
14. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation.
Zhang Y; McCormick LL; Desai SR; Wu C; Gilliam AC
J Immunol; 2002 Mar; 168(6):3088-98. PubMed ID: 11884483
[TBL] [Abstract][Full Text] [Related]
15. Induction of oral tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murine model.
Ilan Y; Gotsman I; Pines M; Beinart R; Zeira M; Ohana M; Rabbani E; Engelhardt D; Nagler A
Blood; 2000 Jun; 95(11):3613-9. PubMed ID: 10828052
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model.
Morin F; Kavian N; Marut W; Chéreau C; Cerles O; Grange P; Weill B; Nicco C; Batteux F
J Invest Dermatol; 2015 Oct; 135(10):2385-2393. PubMed ID: 25938558
[TBL] [Abstract][Full Text] [Related]
17. Imatinib for sclerodermatous graft-versus-host disease in lung transplantation.
Zhang J; Chen F; Ueki T; Date H
Interact Cardiovasc Thorac Surg; 2015 Aug; 21(2):260-2. PubMed ID: 25972597
[TBL] [Abstract][Full Text] [Related]
18. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
Flynn R; Paz K; Du J; Reichenbach DK; Taylor PA; Panoskaltsis-Mortari A; Vulic A; Luznik L; MacDonald KK; Hill GR; Nyuydzefe MS; Weiss JM; Chen W; Trzeciak A; Serody JS; Aguilar EG; Murphy WJ; Maillard I; Munn D; Koreth J; Cutler CS; Antin JH; Ritz J; Waksal SD; Zanin-Zhorov A; Blazar BR
Blood; 2016 Apr; 127(17):2144-54. PubMed ID: 26983850
[TBL] [Abstract][Full Text] [Related]
19. Preventive effect of ultraviolet radiation on murine chronic sclerodermatous graft-versus-host disease.
Mermet I; Kleinclauss F; Marandin A; Guérrini JS; Angonin R; Tiberghien P; Saas P; Aubin F
Transplantation; 2007 Dec; 84(12):1696-700. PubMed ID: 18165783
[TBL] [Abstract][Full Text] [Related]
20. Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.
Chen X; Wang Y; Huang X; Geng S; Li C; Zeng L; Huang L; Du X; Weng J; Lai P
Int Immunopharmacol; 2023 Apr; 117():109746. PubMed ID: 36827923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
